GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Short-Term Debt

Lin BioScience (ROCO:6696) Short-Term Debt : NT$0.00 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Short-Term Debt?

Lin BioScience's Short-Term Debt for the quarter that ended in Jun. 2023 was NT$0.00 Mil.


Lin BioScience Short-Term Debt Historical Data

The historical data trend for Lin BioScience's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Short-Term Debt Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lin BioScience Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Lin BioScience Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Lin BioScience (ROCO:6696) Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines